Loading
companiesCompany
HUYABIO International
HUYABIO is a San Diego company that licenses Chinese-discovered medicines for the rest of the world; its lead is tucidinostat, the oral HDAC inhibitor approved in China and Japan for T-cell lymphoma, which it took into a phase 3 trial in melanoma with a checkpoint inhibitor.
Also called: HUYABIO International, LLC.HUYA Bioscience InternationalHUYABIO
Overview
HUYABIO International, based in San Diego, in-licenses drug candidates from Chinese companies and develops them outside China. Its lead compound tucidinostat (HBI-8000, chidamide), a class I HDAC inhibitor approved in China for peripheral T-cell lymphoma and breast cancer and in Japan for lymphoma, was tested with nivolumab in the phase 3 trial registered on ClinicalTrials.gov under HUYABIO as lead sponsor.
Headquarters
San Diego, CA, US
Scorecard
All companies#147of 1244 companies, score 40
- approved products +6
- modalities +2
- regions +2
- registry trials +30
1 approved, 0 in phase 3, 0 earlier, 0 targets, 230 registry studies. Formula on the scorecards page.
Type
Stage
Large private
Website
ApprovedSmall-molecule oral subtype-selective HDAC inhibitor
Tucidinostat (chidamide) · Epidaza
Chidamide, approved in 2014, was the first epigenetic cancer drug invented in China and the first oral drug of its kind anywhere, used for T-cell lymphoma and, with hormone therapy, for breast cancer.
Similar pages
- TrialA Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
- TrialChidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Shares Tucidinostat (chidamide), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma).
- TrialTucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
Shares Chipscreen Biosciences, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma).
- CompanyHiberCell
Shares Pivotal (registrational) trial, Clinical trial, Melanoma.
- CompanyPregLem
- CompanyIdera Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Melanoma.
- CompanyAgennix
- TrialA Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Shares Tucidinostat (chidamide), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma).
cancers
drugs
ApprovedSmall-molecule oral subtype-selective HDAC inhibitor
Tucidinostat (chidamide) · Epidaza